New drug cocktail aims to stop cervical cancer return
NCT ID NCT07368985
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether adding pembrolizumab and lenvatinib to standard chemoradiation and brachytherapy can improve outcomes for adults with high-risk locally advanced cervical cancer. About 87 participants will receive the drug combination and be followed for two years to see if the cancer progresses. The study also tracks side effects to assess safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab and lenvatinib
What this could lead to
If successful, this combination could improve the chance of keeping cervical cancer from coming back for at least two years after standard treatment.
What could go wrong
This is a small, early-phase trial with no control group, so results may not be definitive. The drugs can cause side effects like high blood pressure, fatigue, and immune-related reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER BY FIGO STAGE 2018 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Erasmus MC
Rotterdam, South Holland, 3015 GD, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••